Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study to Evaluate ALN-2232 in Participants With Obesity

Eli Lilly · Phase 1/2 · Recruiting · Enrollment 156

NCT07463846

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part A: ALN-2232n/rn/rn/rn/r
Part A: Placebon/rn/rn/rn/r
Part B: ALN-2232n/rn/rn/rn/r
Part B: Placebon/rn/rn/rn/r
Part C: ALN-2232n/rn/rn/rn/r
Part C: Placebon/rn/rn/rn/r
Part C: Tirzepatiden/rn/rn/rn/r

Not shown

  • Part A: ALN-2232: endpoint not reported
  • Part A: Placebo: endpoint not reported
  • Part B: ALN-2232: endpoint not reported
  • Part B: Placebo: endpoint not reported
  • Part C: ALN-2232: endpoint not reported
  • Part C: Placebo: endpoint not reported
  • Part C: Tirzepatide: endpoint not reported